Identification of Epithelial Mesenchymal Transition-Related LncRNAs Associated with Prognosis and Tumor Immune Microenvironment of Hepatocellular Carcinoma

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2022 Feb 3

PMID 35111268

Authors

Yongjie Zhou

Liangwen Wang

Wen Zhang

Jingqin Ma

Zihan Zhang

Minjie Yang

Jiaze Yu

Jianjun Luo

Zhiping Yan

Affiliations

Soon will be listed here.

Abstract

Purpose: The long noncoding RNAs (lncRNAs) play the important role in tumor occurrence and progression, and the epithelial to mesenchymal transition (EMT) is the critical process for tumor migration. However, the role of EMT-related lncRNA in hepatocellular carcinoma (HCC) has not been elucidated.

Methods: In this study, we selected the EMT-related lncRNAs in HCC by using data from The Cancer Genome Atlas database (TCGA). Two prognostic models of the overall survival (OS) and relapse-free survival (RFS) were constructed and validated through Cox regression model, Kaplan-Meier analysis, and the receiver-operating characteristic (ROC) curves. The unsupervised clustering analysis was utilized to investigate the association between EMT-lncRNAs with tumor immune microenvironment. ESTIMATE algorithm and gene set enrichment analysis (GSEA) were used to estimate tumor microenvironment and associated KEGG pathways.

Results: Two EMT-related lncRNA prognostic models of OS and RFS were constructed. Kaplan-Meier curves showed the dismal prognosis of OS and RFS in the group with high-risk score. The ROC curves and AUC values in two prognostic models indicated the discriminative value in the training set and validation set. Patients with HCC were clustered into two subgroups according the unsupervised clustering analysis. Lnc-CCNY-1 was selected as the key lncRNA. GSVA analysis showed that lnc-CCNY-1 was negatively associated with peroxisome proliferator-activated receptor (PPAR) signaling pathway and positively correlated with CELL cycle pathway.

Conclusion: Two EMT-related lncRNA prognostic models of OS and RFS were constructed to discriminate patients and predict prognosis of HCC. EMT-related lncRNAs may play a role on prognosis of HCC by influencing the immune microenvironment. Lnc-CCNY-1 was selected as the key EMT-related lncRNA for further exploration.

Citing Articles

The clinical significance, immune infiltration, and tumor mutational burden of angiogenesis-associated lncRNAs in kidney renal clear cell carcinoma.

Zhang W, Liu Z, Wang J, Geng B, Hou W, Zhao E Front Immunol. 2022; 13:934387.

PMID: 35958561 PMC: 9360495. DOI: 10.3389/fimmu.2022.934387.

References

Xu D, Yang F, Yuan J, Zhang L, Bi H, Zhou C . Long noncoding RNAs associated with liver regeneration 1 accelerates hepatocyte proliferation during liver regeneration by activating Wnt/β-catenin signaling. Hepatology. 2013; 58(2):739-51. DOI: 10.1002/hep.26361. View

Peng L, Chen Y, Ou Q, Wang X, Tang N . LncRNA MIAT correlates with immune infiltrates and drug reactions in hepatocellular carcinoma. Int Immunopharmacol. 2020; 89(Pt A):107071. DOI: 10.1016/j.intimp.2020.107071. View

Wang Y, Liu Z, Yao B, Li Q, Wang L, Wang C . Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis. Mol Cancer. 2017; 16(1):123. PMC: 5514467. DOI: 10.1186/s12943-017-0702-z. View

Curran M, Montalvo W, Yagita H, Allison J . PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010; 107(9):4275-80. PMC: 2840093. DOI: 10.1073/pnas.0915174107. View

Lee H, Chu K, Moon E, Kim S, Quan F . Sensitization to oxidative stress and G2/M cell cycle arrest by histone deacetylase inhibition in hepatocellular carcinoma cells. Free Radic Biol Med. 2019; 147:129-138. DOI: 10.1016/j.freeradbiomed.2019.12.021. View

Lin L, Yao Z, Bhuvaneshwar K, Gusev Y, Kallakury B, Yang S . Transcriptional regulation of STAT3 by SPTBN1 and SMAD3 in HCC through cAMP-response element-binding proteins ATF3 and CREB2. Carcinogenesis. 2014; 35(11):2393-403. DOI: 10.1093/carcin/bgu163. View

Langhans B, Nischalke H, Kramer B, Dold L, Lutz P, Mohr R . Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma. Cancer Immunol Immunother. 2019; 68(12):2055-2066. PMC: 11028391. DOI: 10.1007/s00262-019-02427-4. View

Liang W, Ren J, Wong C, Chan S, Waye M, Fu W . LncRNA-NEF antagonized epithelial to mesenchymal transition and cancer metastasis via cis-regulating FOXA2 and inactivating Wnt/β-catenin signaling. Oncogene. 2018; 37(11):1445-1456. DOI: 10.1038/s41388-017-0041-y. View

Yuan Y . Spatial Heterogeneity in the Tumor Microenvironment. Cold Spring Harb Perspect Med. 2016; 6(8). PMC: 4968167. DOI: 10.1101/cshperspect.a026583. View

10.

Rhim A, Mirek E, Aiello N, Maitra A, Bailey J, McAllister F . EMT and dissemination precede pancreatic tumor formation. Cell. 2012; 148(1-2):349-61. PMC: 3266542. DOI: 10.1016/j.cell.2011.11.025. View

11.

Yao R, Li J, Zhang R, Chen R, Wang Y . M2-polarized tumor-associated macrophages facilitated migration and epithelial-mesenchymal transition of HCC cells via the TLR4/STAT3 signaling pathway. World J Surg Oncol. 2018; 16(1):9. PMC: 5771014. DOI: 10.1186/s12957-018-1312-y. View

12.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

13.

Harding J, Abu-Zeinah G, Chou J, Owen D, Ly M, Lowery M . Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. J Natl Compr Canc Netw. 2018; 16(1):50-58. DOI: 10.6004/jnccn.2017.7024. View

14.

Schmitt A, Chang H . Long Noncoding RNAs in Cancer Pathways. Cancer Cell. 2016; 29(4):452-463. PMC: 4831138. DOI: 10.1016/j.ccell.2016.03.010. View

15.

Newman A, Steen C, Liu C, Gentles A, Chaudhuri A, Scherer F . Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019; 37(7):773-782. PMC: 6610714. DOI: 10.1038/s41587-019-0114-2. View

16.

Fu Y, Liu S, Zeng S, Shen H . From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res. 2019; 38(1):396. PMC: 6734524. DOI: 10.1186/s13046-019-1396-4. View

17.

Hsu C, Wu L, Hsia C, Yin P, Chi C, Yeh T . Energy metabolism determines the sensitivity of human hepatocellular carcinoma cells to mitochondrial inhibitors and biguanide drugs. Oncol Rep. 2015; 34(3):1620-8. DOI: 10.3892/or.2015.4092. View

18.

Zhai Q, Qin J, Jin X, Sun X, Wang L, Du W . PADI4 modulates the invasion and migration of osteosarcoma cells by down-regulation of epithelial-mesenchymal transition. Life Sci. 2020; 256:117968. DOI: 10.1016/j.lfs.2020.117968. View

19.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

20.

Yan X, Zhang D, Wu W, Wu S, Qian J, Hao Y . Mesenchymal Stem Cells Promote Hepatocarcinogenesis via lncRNA-MUF Interaction with ANXA2 and miR-34a. Cancer Res. 2017; 77(23):6704-6716. DOI: 10.1158/0008-5472.CAN-17-1915. View